You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

ADALAT CC Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Adalat Cc patents expire, and what generic alternatives are available?

Adalat Cc is a drug marketed by Norwich and is included in one NDA.

The generic ingredient in ADALAT CC is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the nifedipine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Adalat Cc

A generic version of ADALAT CC was approved as nifedipine by ACTAVIS ELIZABETH on January 8th, 1991.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ADALAT CC?
  • What are the global sales for ADALAT CC?
  • What is Average Wholesale Price for ADALAT CC?
Summary for ADALAT CC
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 165
Clinical Trials: 29
Patent Applications: 274
Drug Prices: Drug price information for ADALAT CC
What excipients (inactive ingredients) are in ADALAT CC?ADALAT CC excipients list
DailyMed Link:ADALAT CC at DailyMed
Drug patent expirations by year for ADALAT CC
Drug Prices for ADALAT CC

See drug prices for ADALAT CC

Drug Sales Revenue Trends for ADALAT CC

See drug sales revenues for ADALAT CC

Recent Clinical Trials for ADALAT CC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cao YuPhase 1
Jing LiuPhase 4
Gundersen Health SystemPhase 4

See all ADALAT CC clinical trials

US Patents and Regulatory Information for ADALAT CC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Norwich ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-001 Apr 21, 1993 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Norwich ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-002 Apr 21, 1993 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Norwich ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-003 Apr 21, 1993 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ADALAT CC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Norwich ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-002 Apr 21, 1993 ⤷  Sign Up ⤷  Sign Up
Norwich ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-001 Apr 21, 1993 ⤷  Sign Up ⤷  Sign Up
Norwich ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-002 Apr 21, 1993 ⤷  Sign Up ⤷  Sign Up
Norwich ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-003 Apr 21, 1993 ⤷  Sign Up ⤷  Sign Up
Norwich ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-001 Apr 21, 1993 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.